我国口服降糖药市场竞争激烈,二甲双胍、达格列净销售额位居前列。达格列净二甲双胍缓释片是一种新型口服降糖复方制剂,结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净为SGLT-2(钠-葡萄糖协同转运蛋白-2)抑制剂,通过抑制SGLT-2蛋白,减少肾脏重吸收葡萄糖,促进尿糖排泄,来达到降低血糖的目的。双胍类降糖药二甲双胍是目前治疗2型糖尿病(T2DM)的一线药物,双胍类降糖药属于胰岛素增敏剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.